Provider Perspectives on BTKi Selection in CLL

Provider Perspectives on BTKi Selection in CLL

In this episode of OncoTalks, Dr. Yair Levy shares his approach to BTKi selection for patients with chronic lymphocytic leukemia (CLL), highlighting the growing role of second-generation BTK inhibitors, and the importance of tailoring treatment to individual patient characteristics. The discussion also explores the challenges providers face when navigating insurance requirements, medication access, and long-term adherence. Learn how thoughtful treatment selection and patient-centered education can help improve outcomes throughout the CLL treatment journey. Listen to Navigating the CLL Treatment Landscape: The Role of Physician Choice [https://oncotalks.podbean.com/e/navigating-the-cll-treatment-landscape-the-role-of-physician-choice/] as Dr. Levy discusses why preserving physician autonomy is essential to delivering optimal, patient-centered oncology care. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Navigating the CLL Treatment Landscape: The Role of Physician Choice

In this episode of OncoTalks, host Tulsi Patel is joined by Dr. Yair Levy to discuss the growing impact of utilization management policies on chronic lymphocytic leukemia (CLL) care. As treatment options expand, personalized therapy selection is more critical than ever, yet step therapy requirements and payer restrictions are increasingly shaping clinical decisions. Dr. Levy shares real-world insights on how these policies affect patient outcomes, treatment adherence, and provider workload. Tune in to explore why preserving physician autonomy is essential to delivering optimal, patient-centered oncology care. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Navigating Maximum Fair Price in Prostate Cancer Care

In this episode of OncoTalks, host Tulsi Patel speaks with Brandon Dyson, PharmD, BCOP, BCPS, Director of Pharmacy Education at Texas Oncology, about how the Maximum Fair Price (MFP) program may influence prostate cancer care in community oncology. They review therapies selected for MFP regulation, key implementation timelines, and share practical steps oncology providers and practices can take now to prepare. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Sacituzumab Govitecan: Advancing the Role of ADCs in Breast Cancer

In this episode of OncoTalks, host Tulsi Patel speaks with Dr. Hope Rugo about the evolving role of antibody‑drug conjugates (ADCs) in breast cancer, with a focus on sacituzumab govitecan, the first and currently only approved ADC for patients with previously treated metastatic triple‑negative breast cancer (mTNBC). Dr. Rugo highlights key clinical data supporting its approvals in mTNBC and HR‑positive/HER2‑negative disease, and discusses indications, efficacy, safety considerations, and emerging first‑line trial findings that may influence future treatment sequencing. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

From Guidelines to Practice: Navigating Biomarker Testing in NSCLC

In this episode of OncoTalks, host Dr. Ira Zackon is joined by Dr. Alexander Spira to discuss comprehensive biomarker testing in non-small cell lung cancer (NSCLC). They unpack key findings from a recent study revealing variability in testing practices and emphasize the importance of comprehensive DNA- and RNA-based next-generation sequencing over single-gene testing. Tune in to review the latest clinical guidelines, learn how testing impacts treatment sequencing, and glean insights into how community oncology practices can overcome barriers to ensure that all NSCLC patients receive guideline-concordant testing and treatment.   Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.